ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

By Defending Potti, Duke Officials Become Target Of Charges Of Institutional Failure

July 23, 2010

MD Anderson Survey Shows Faculty Dissatisfaction with Top Leaders

May 23, 2014

New RFAs on Retinoids & Carotenoids, Tobacco, NMR Research Resistance

July 27, 1984

Virus Studies Approved By DCE Board for $2.5 Mil. In First Year

November 3, 1989

In Brief: Reagan/Congress Budget Compromise Seems Likely, Would Loosen FY 1982 Spending Limits On NCI

December 11, 1981

Adding Topotecan To Standard Treatment Doesn’t Improve Progression-Free Survival

October 29, 2010